scispace - formally typeset
R

Roman Lesyk

Researcher at Danylo Halytsky Lviv National Medical University

Publications -  229
Citations -  4213

Roman Lesyk is an academic researcher from Danylo Halytsky Lviv National Medical University. The author has contributed to research in topics: Chemistry & Thiazole. The author has an hindex of 31, co-authored 191 publications receiving 3318 citations.

Papers
More filters
Journal ArticleDOI

Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity.

TL;DR: The most efficient anticancer compound 16 was found to be active with selective influence on colon cancer cell lines, especially on HT 29 (logGI(50)=-6.37) and in vitro anticancer activity of synthesized compounds were tested by the National Cancer Institute.
Journal ArticleDOI

Synthesis and anticancer activity evaluation of 4-thiazolidinones containing benzothiazole moiety

TL;DR: In vitro anticancer activity of the synthesized compounds was tested by the National Cancer Institute and two of them has revealed the antic cancer activity on leukemia, melanoma, lung, colon, CNS, ovarian, renal, prostate and breast cancers cell lines.
Journal ArticleDOI

Synthesis of new 4-thiazolidinone-, pyrazoline-, and isatin-based conjugates with promising antitumor activity.

TL;DR: The most effective anticancer compound 10 was found to be active with mean GI₅₀ and TGI values of 0.071 μM and 0.76 μM, respectively and demonstrated the highest antiproliferative influence on the non-small-cell lung cancer cell line HOP-92.
Journal ArticleDOI

New 5-substituted thiazolo[3,2-b][1,2,4]triazol-6-ones: synthesis and anticancer evaluation.

TL;DR: It was shown that 5-ylidene-[1,3]thiazolo[3,2-b][1,2,4]triazol-6-ones are characterized with more potent anticancer activity than respective amides.
Journal ArticleDOI

5-Ene-4-thiazolidinones - An efficient tool in medicinal chemistry.

TL;DR: The main directions for active 5-ene-4-thiazolidinones optimization have been shown: i) complication of the fragment in the C5 position; ii) introduction of the substituents in the N3 position; iii) annealing in complex heterocyclic systems; iv) combination with other pharmacologically attractive fragments within hybrid pharmacophore approach.